biostudies-literatureSang L111 Incubation ProjectMajor Discipline Academic and Technical Leaders Training Program of Jiangxi ProvinceNational Natural Science Foundation of China247-262https://www.ebi.ac.uk/biostudies/studies/S-EPMC10879352biostudies-literatureUnknown41(2)<h4>Objective</h4>Antineoplastic agent-induced systolic dysfunction is a major reason for interruption of anticancer treatment. Although targeted anticancer agents infrequently cause systolic dysfunction, their combinations with chemotherapies remarkably increase the incidence. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide a potent in vitro model to assess cardiovascular safety. However, quantitatively predicting the reduction of ejection fraction based on hiPSC-CMs is challenging due to the absence of the body's regulatory response to cardiomyocyte injury.<h4>Methods</h4>Here, we developed and validated an in vitro-in vivo translational platform to assess the reduction of ejection fraction induced by antineoplastic drugs based on hiPSC-CMs. The translationPharmaceutical researchAn In Silico Platform to Predict Cardiotoxicity Risk of Anti-tumor Drug Combination with hiPSC-CMs Based In Vitro Study.PMC1087935220212BCJ2302581973391BC201802481773826Qian HHao KZhang YHe HLuo SZhou YSang LZhou ZfalseAn In Silico Platform to Predict Cardiotoxicity Risk of Anti-tumor Drug Combination with hiPSC-CMs Based In Vitro Study.<h4>Objective</h4>Antineoplastic agent-induced systolic dysfunction is a major reason for interruption of anticancer treatment. Although targeted anticancer agents infrequently cause systolic dysfunction, their combinations with chemotherapies remarkably increase the incidence. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide a potent in vitro model to assess cardiovascular safety. However, quantitatively predicting the reduction of ejection fraction based on hiPSC-CMs is challenging due to the absence of the body's regulatory response to cardiomyocyte injury.<h4>Methods</h4>Here, we developed and validated an in vitro-in vivo translational platform to assess the reduction of ejection fraction induced by antineoplastic drugs based on hiPSC-CMs. The translation2024-01-01T00:00:00Z2024 Feb2026-06-10T09:25:12.701Z2025-04-06T12:32:42.61ZS-EPMC108793523814838410.1007/s11095-023-03644-4